NCT02516267

Evaluation of Platelet Aggregability in the Release of CABG in Patients With ACS With DAPT.

The Importance of Evaluation of Platelet Aggregability in the Release of Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome With Dual Antiplatelet Therapy.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 190 (actual)
• Sponsor: University of Sao Paulo General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess platelet aggregability by a "point of care" device (Multiplate®) to decrease the release time for coronary artery bypass graft (CABG ) in patients with acute coronary syndrome (ACS) in use of dual antiplatelet therapy.

Detailed description

This open, prospective, randomized study will be included patients with acute coronary syndrome (ACS) and coronary artery bypass graft (CABG) indication in use of double platelet aggregation (aspirin and inhibitor of ADP). The groups to be analyzed will be: 1. Control group: It is composed of patients who will discontinue inhibitor of ADP for 5 days before surgery, and must be operated on the first working day after completing the 5 days without the drug. This group will have aggregability evaluated by platelet function testing (Multiplate®) immediately before the transport to the operating room. 2. Intervention group: It is composed of patients who will be evaluated by platelet function testing (Multiplate®) daily until the value obtained\> 46 AU, when they will be immediately released to CABG, to be held on the first working day after release. All patients included, after the explanations and signing the informed consent, will initially undergo preoperative examinations as institutional routine. In the immediate period (24 hours) after CABG will be collected on all results of tests to which the patient is submitted in accordance with the institutional routines, and the volume of chest tube bleeding and need for blood transfusions. Clinical data "MACE" will be collected throughout the patient's hospital stay.

Conditions

• Bleeding

Interventions

Type	Name	Description
DEVICE	Multiplate ADP®	Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained\> 46 AU, when they will be immediately released to CABG

Timeline

• Start date: 2015-07-01
• Primary completion: 2015-07-01
• Completion: 2019-01-01
• First posted: 2015-08-05
• Last updated: 2020-03-24

Locations

1 site across 1 country: Brazil